Cargando…
Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review
INTRODUCTION: Stage III melanoma, also referred to as regional metastatic melanoma, has five-year survival rates ranging between 40% and 78%. In order to reduce the likelihood of recurrence in this high-risk population, patients undergo resection of primary tumors and all involved nodal basins. Syst...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963921/ https://www.ncbi.nlm.nih.gov/pubmed/21042541 |